一分钟看懂
这是一项关于淋巴瘤的I 期研究，登记的药物或干预包括XS-04 tablet，当前状态为招募中。登记地点显示中国北京、广东省、河北省、湖北省有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
XS-04 tablet · I 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至75 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Sun Yat-sen University Cancer Center · 广东省
- Affiliated Hospital of Hebei University · 河北省
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 湖北省
公开的入选条件
- Patients must meet all of the following conditions to be enrolled:
- * Voluntarily participate in the clinical trial and sign the informed consent form (ICF).
- * Age ≥18 years, ≤75 years, regardless of gender.
- * Dose escalation phase: Patients with mature B-cell malignant tumors confirmed by histopathology according to the 2017 World Health Organization (WHO) classification, who have failed existing treatments and have no suitable treatment options and have treatmen
- Dose expansion phase: Patients with B-cell lymphoma confirmed by histopathology according to the 2017 WHO classification (cohort 1 includes DLBCL patients, cohort 2 includes other B-cell lymphoma patients), and patients with myeloid tumors confirmed according
- Meet the following disease-specific criteria (tumor types not listed below will be discussed by the sponsor and the investigators to decide if they can be enrolled):
- 1. For indolent B-NHL (follicular lymphoma \[FL\], marginal zone lymphoma \[MZL\], and Waldenström macroglobulinemia \[WM\]), patients must have received at least two lines of systemic therapy, including at least one line of combination therapy containing anti
- 2. For AML, diagnosed according to the 2016 World Health Organization (WHO) classification, meeting the definition of relapsed/refractory as per the "Chinese Guidelines for the Diagnosis and Treatment of Relapsed/Refractory Acute Myeloid Leukemia (2021 Edition
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06820268；登记信息更新于 2026-09-25。